Semaglutide vs Tirzepatide vs Retatrutide: What Actually Separates Them

Every week someone asks which of these three is best. It is the wrong question, and answering it properly takes about five minutes. The three compounds are not different strengths of the same thing. They act on different combinations of receptors, and that combination is what determines how they feel to run, how the side-effect load lands, and what happens to body composition rather than just to the number on the scale.

The receptors are the whole story

There are three incretin and metabolic receptors in play here: GLP-1, GIP and the glucagon receptor. GLP-1 slows gastric emptying, increases satiety signalling and improves glucose-dependent insulin release. GIP is the other major incretin — its role in appetite is more complicated, but adding it appears to reduce the nausea burden while improving how much fat mass is lost relative to lean mass. The glucagon receptor is the newest addition, and it is the one associated with increased energy expenditure rather than reduced intake.

Once you hold those three in your head, the three compounds sort themselves out immediately.

Semaglutide: one receptor, the most data

Semaglutide is a GLP-1 receptor agonist and nothing else. It is also the compound with the longest and deepest clinical record of the three, which is not a small thing — the safety picture is better characterised than for anything newer.

Practically, semaglutide is the most predictable of the three. Appetite suppression arrives fast and it is blunt. Most people describe it as food simply becoming uninteresting. The trade-off is that a single-receptor mechanism concentrates the gastrointestinal side effects, and the titration schedule exists precisely to manage that. It is also the one most likely to cost lean mass if protein intake and resistance training are neglected, because there is nothing in the mechanism working in the other direction.

It remains the right starting point for most people, particularly anyone who has never run a GLP-1 before.

Tirzepatide: two receptors, a different appetite profile

Tirzepatide is a dual GIP and GLP-1 receptor agonist. In head-to-head trial data it produces greater average weight reduction than semaglutide, but the more interesting difference is qualitative rather than quantitative.

People running tirzepatide typically report appetite suppression that feels less like nausea and more like normal, early satiety. Meals end sooner rather than becoming repellent. The addition of GIP agonism appears to be what buys that, and it is also part of why the nausea burden is often lower at comparable efficacy.

The practical cost is a longer titration ladder. Tirzepatide has more dose steps than semaglutide, which means more time before you reach a maintenance dose, and more opportunities to move up too fast and undo the tolerability advantage.

Retatrutide: three receptors, the newest data

Retatrutide adds glucagon receptor agonism on top of GIP and GLP-1. That third receptor changes the shape of the mechanism: instead of only reducing intake, it also raises energy expenditure. Early trial results have been the most dramatic of the three by a meaningful margin.

It is also, by a distance, the least established. The clinical record is thinner, the long-term safety picture is less complete, and glucagon receptor agonism brings its own considerations — heart rate and hepatic glucose output among them. That is not a reason to avoid it. It is a reason to run it with bloodwork and a provider watching, rather than because a video said it was the strongest one.

The comparison that actually matters

Notice what is not in that table: a winner. The compound that works is the one you can actually stay on for long enough to matter, at a dose you tolerate, while eating enough protein and lifting something heavy twice a week.

Side effects are a titration problem

Nearly every bad experience we hear about traces back to the same cause: someone moved up a dose because the calendar said so rather than because the last one was comfortable. Nausea, reflux, constipation and fatigue are almost always dose-rate problems, not compound problems.

If the current dose is not comfortable, the next dose is not the answer. Hold, extend the block, and move when your body has caught up — not when the box runs out.

The second most common cause is dehydration. Appetite suppression suppresses thirst signalling alongside hunger, and a lot of what gets reported as fatigue is simply not drinking enough water.

How to choose

If you have never run a GLP-1: start with semaglutide, at the lowest dose, and give it eight weeks before judging it.

If you have run semaglutide and either plateaued or could not tolerate it: tirzepatide is the logical next step, and the GIP component is the specific reason.

If you have run both, are being monitored, and have a reason beyond curiosity: retatrutide is worth the conversation with your provider.

Whichever you pick, get baseline bloodwork first. Not because it is a formality, but because without a starting number you have no way of knowing whether the thing is working or whether you simply lost water weight in week two.